View ValuationCarasent 将来の成長Future 基準チェック /46Carasent利益と収益がそれぞれ年間40.9%と16.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に8.1% 37.5%なると予測されています。主要情報40.9%収益成長率37.52%EPS成長率Healthcare Services 収益成長20.0%収益成長率16.3%将来の株主資本利益率8.14%アナリストカバレッジLow最終更新日13 Jul 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Jul 14Second quarter 2026 earnings released: kr0.04 loss per share (vs kr0.08 loss in 2Q 2025)Second quarter 2026 results: kr0.04 loss per share (improved from kr0.08 loss in 2Q 2025). Revenue: kr97.7m (up 18% from 2Q 2025). Net loss: kr2.76m (loss narrowed 50% from 2Q 2025). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Board Change • May 20High number of new directorsIndependent Director Cecilia Lager was the last director to join the board, commencing their role in 2025.お知らせ • Apr 28Carasent AB (publ) (OM:CARA) agreed to acquire Infosolutions Sverige Ab for an enterprise value of approximately SEK 120 million.Carasent AB (publ) (OM:CARA) agreed to acquire Infosolutions Sverige Ab for an enterprise value of approximately SEK 120 million on April 27, 2026. A cash consideration will be paid by Carasent AB (publ). The purchase price will be paid 90 percent in cash and 10 percent in already repurchased Carasent shares, valued at SEK 23.74 per share based on a 90-day volume-weighted average price (VWAP), corresponding to 538,555 shares. For the period ending December 31, 2025, Infosolutions Sverige Ab reported total revenue of SEK 67 million. The expected completion of the transaction is April 27, 2026 to June 30, 2026.お知らせ • Feb 12+ 3 more updatesCarasent AB (publ) to Report Q4, 2026 Results on Feb 04, 2027Carasent AB (publ) announced that they will report Q4, 2026 results on Feb 04, 2027お知らせ • Feb 09Carasent AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Carasent AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 12, 2026お知らせ • Dec 17Carasent AB (publ) (OM:CARA) announces an Equity Buyback for 10% of its issued share capital.Carasent ASA (OB:CARA) commences share repurchases on December 16, 2025, under the program mandated by shareholders in the Annual General Meeting held on April 23, 2025. As per the mandate, the company is authorized to repurchase up to 10% of its issued share capital, such that the company’s holding in treasury together with the shares repurchased does not exceed 10% of its issued share capital at any point of time. The purpose of the program is transfer of shares may be made with deviation from shareholders' preferential rights is to enable financing of acquisitions. On July 9, 2025, the company initiated a Market repurchases. Under the program, the company will repurchase up to SEK 150 million worth of its shares. The payment for acquired shares shall be made in cash. The repurchases may last until the 2026 Annual General Meeting at the latest.お知らせ • Oct 23Carasent AB (publ), Annual General Meeting, Apr 20, 2026Carasent AB (publ), Annual General Meeting, Apr 20, 2026. Location: stockholm Swedenお知らせ • Oct 10Carasent AB (publ) to Report Q3, 2025 Results on Oct 16, 2025Carasent AB (publ) announced that they will report Q3, 2025 results at 7:00 AM, Central European Standard Time on Oct 16, 2025お知らせ • Jul 08Carasent AB (publ) to Report Q2, 2025 Results on Jul 10, 2025Carasent AB (publ) announced that they will report Q2, 2025 results at 7:00 AM, Central European Standard Time on Jul 10, 2025お知らせ • Apr 24Carasent AB (Publ) Announces Board AppointmentsCarasent AB (publ) at its Annual General Meeting on 23 April 2025, approved to elect Johan Kallblad, Dr. Carol Wildhagen and Cecilia Lager as new Board members, and to elect Tomas Meerits as the Chairman of the Board.お知らせ • Apr 08Carasent AB (publ) to Report Q1, 2025 Results on Apr 11, 2025Carasent AB (publ) announced that they will report Q1, 2025 results at 7:00 AM, Central European Standard Time on Apr 11, 2025お知らせ • Feb 24Carasent AB (publ), Annual General Meeting, Apr 23, 2025Carasent AB (publ), Annual General Meeting, Apr 23, 2025.お知らせ • Oct 29Carasent ASA (OB:CARA) acquired Data - Al GmbH.Carasent ASA (OB:CARA) acquired Data - Al GmbH on October 28, 2024. The transaction values DataAl at an enterprise value of €8 million, with potential additional earnout payments of up to €4 million pending future growth. Data - Al has reported revenues of approximately €4 million and EBITDA of approximately €0.5 million in 2023. Carasent ASA (OB:CARA) completed the acquisition of Data - Al GmbH on October 28, 2024.Reported Earnings • Oct 25Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023)Third quarter 2024 results: kr0.03 loss per share (improved from kr0.06 loss in 3Q 2023). Revenue: kr66.3m (up 19% from 3Q 2023). Net loss: kr2.03m (loss narrowed 55% from 3Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.New Risk • Sep 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).Board Change • Jul 30High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Ulrika Sundling is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 01Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion on April 4, 2024. Offer price per share is NOK 20. The transaction is subject to subject to customary conditions, including acceptance level and any regulatory approvals required. The Offer has already received strong support from key shareholders representing 34% of the share capital of Carasent. Launch of the Offer is subject to, inter alia, a customary confirmatory due diligence of key commercial, financial, technical and legal aspects of Carasent with a focus on confirming key assumptions. The board of directors advises all shareholders to monitor the situation but not take any action in respect of the offer which may be made by EG until shareholders can assess the merits of such offer on the basis of further developments. DNB Markets acted as financial advisor and Advokatfirmaet BAHR AS acted as legal advisor to Carasent. Carnegie AS acted as financial advisor and Arntzen de Besche acted as legal advisor to Eg Norge.Reported Earnings • Apr 26First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)First quarter 2024 results: kr0.15 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr66.9m (up 12% from 1Q 2023). Net loss: kr10.6m (loss widened kr9.52m from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 20Carasent ASA Announces Changes to Its BoardCarasent ASA, at its Annual General Meeting held on April 17, 2024, approved the following. In accordance with the proposal from the Company's Nomination Committee, Henric Carlsson elected as a new Director for a period of two years, cf. the Public Limited Liability Companies Act § 6-6. The new Board of Directors consists of: Petri Niemi, Chairman; Camilla Skoog; Ulrika Cederskog Sundling; Tomas Meerits; Henric Carlsson. In accordance with the proposal from the Company's Board of Directors and Nomination Committee, Jesper Jannerberg and Peder Strand elected as new members of the Committee for a period of two years.Reported Earnings • Mar 25Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)Full year 2023 results: kr0.60 loss per share (down from kr0.39 profit in FY 2022). Revenue: kr244.0m (up 25% from FY 2022). Net loss: kr46.4m (down 249% from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Feb 26Chief Executive Officer recently bought €121k worth of stockOn the 23rd of February, Daniel Ohman bought around 135k shares on-market at roughly €0.89 per share. This transaction increased Daniel's direct individual holding by 5x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth €2.4m. Daniel has been a buyer over the last 12 months, purchasing a net total of €137k worth in shares.Reported Earnings • Feb 16Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)Full year 2023 results: kr0.64 loss per share (down from kr0.39 profit in FY 2022). Revenue: kr244.0m (up 25% from FY 2022). Net loss: kr46.4m (down 249% from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Feb 01Founder recently bought €2.4m worth of stockOn the 30th of January, Niclas Hugosson bought around 3m shares on-market at roughly €0.95 per share. This transaction increased Niclas' direct individual holding by 552x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Niclas has been a buyer over the last 12 months, purchasing a net total of €2.0m worth in shares.Board Change • Jan 07High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Ulrika Sundling is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.New Risk • Dec 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings are forecast to decline by an average of 1.5% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (€68.9m market cap, or US$75.0m).お知らせ • Nov 30Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of DirectorsCarasent ASA announced that Board member Staffan Hanstorp has given notice of his resignation as a member of the board of directors of Carasent ASA with immediate effect.お知らせ • Nov 25+ 5 more updatesCarasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024Carasent ASA announced that they will report fiscal year 2023 results on Mar 22, 2024お知らせ • Nov 16Carasent Asa Approves DividendCarasent ASA approved dividend of NOK 1.84 per share, totaling NOK 133,077,597 million. The payment is to be based on the approved 2022 Annual Accounts.Reported Earnings • Jul 16Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)Second quarter 2023 results: kr0.64 loss per share (down from kr0.03 profit in 2Q 2022). Revenue: kr63.2m (up 36% from 2Q 2022). Net loss: kr51.3m (down kr53.7m from profit in 2Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare Services industry in Europe.Reported Earnings • May 05First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)First quarter 2023 results: kr0.01 loss per share (down from kr0.32 profit in 1Q 2022). Revenue: kr59.9m (up 34% from 1Q 2022). Net loss: kr1.04m (down 104% from profit in 1Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare Services industry in Europe.Reported Earnings • Apr 06Full year 2022 earnings releasedFull year 2022 results: Revenue: kr195.3m (up 42% from FY 2021). Net income: kr31.2m (up kr31.3m from FY 2021). Profit margin: 16% (up from net loss in FY 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare Services industry in Europe.Reported Earnings • Feb 16Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)Full year 2022 results: EPS: kr0.39 (up from kr0.002 loss in FY 2021). Revenue: kr195.3m (up 42% from FY 2021). Net income: kr31.2m (up kr31.3m from FY 2021). Profit margin: 16% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe.お知らせ • Jan 05+ 5 more updatesCarasent ASA to Report Q1, 2023 Results on May 04, 2023Carasent ASA announced that they will report Q1, 2023 results on May 04, 2023Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. 1 highly experienced director. Independent Chairman of the Board Johan Lindqvist is the most experienced director on the board, commencing their role in 2007. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.64, the stock trades at a forward P/E ratio of 91x. Average forward P/E is 27x in the Healthcare Services industry in Europe. Total loss to shareholders of 60% over the past year.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.13 (up from kr0.28 loss in 3Q 2021). Revenue: kr47.4m (up 28% from 3Q 2021). Net income: kr10.4m (up kr31.8m from 3Q 2021). Profit margin: 22% (up from net loss in 3Q 2021). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare Services industry in Europe.Reported Earnings • Jul 16Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)Second quarter 2022 results: EPS: kr0.03 (down from kr0.34 in 2Q 2021). Net income: kr2.40m (down 88% from 2Q 2021).Valuation Update With 7 Day Price Move • May 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to €2.07, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 29x in the Healthcare Services industry in Europe. Total loss to shareholders of 40% over the past year.Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)First quarter 2022 results: EPS: kr0.32 (up from kr0.14 loss in 1Q 2021). Revenue: kr44.8m (up 59% from 1Q 2021). Net income: kr25.4m (up kr33.1m from 1Q 2021). Profit margin: 57% (up from net loss in 1Q 2021). The move to profitability was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 41%, compared to a 26% growth forecast for the industry in Germany.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Staffan Hanstorp was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 04Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)Full year 2021 results: kr0.002 loss per share (up from kr0.85 loss in FY 2020). Revenue: kr137.1m (up 94% from FY 2020). Net loss: kr148.0k (loss narrowed 100% from FY 2020). Over the next year, revenue is forecast to grow 53%, compared to a 31% growth forecast for the industry in Germany.Reported Earnings • Feb 11Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: kr0.01 (up from kr0.85 loss in FY 2020). Revenue: kr137.1m (up 94% from FY 2020). Net income: kr642.0k (up kr38.8m from FY 2020). Profit margin: 0.5% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 46%, compared to a 44% growth forecast for the industry in Germany.Reported Earnings • Oct 28Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)The company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr36.9m (up 109% from 3Q 2020). Net loss: kr21.4m (loss widened 136% from 3Q 2020).Reported Earnings • Aug 21Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr32.0m (up 88% from 2Q 2020). Net income: kr19.9m (up kr25.5m from 2Q 2020). Profit margin: 62% (up from net loss in 2Q 2020).Executive Departure • Aug 04Chief Financial Officer Lars Forsberg has left the companyOn the 1st of August, Lars Forsberg's tenure as Chief Financial Officer ended. We don't have any record of a personal shareholding under Lars' name. A total of 2 executives have left over the last 12 months.Reported Earnings • May 01First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: kr28.2m (up 81% from 1Q 2020). Net loss: kr7.67m (down kr8.06m from profit in 1Q 2020).Reported Earnings • Mar 29Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: kr70.6m (up 47% from FY 2019). Net loss: kr38.1m (down kr41.3m from profit in FY 2019).お知らせ • Mar 04Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA) on March 2, 2021. As a part of the transaction Aeternum Capital acquired 8.25 million shares. Aeternum Capital AS, a fund managed by Aeternum Management AS completed the acquisition of 15% stake in Carasent ASA (OB:CARA) on March 2, 2021.Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 0.6%. Over the next year, revenue is forecast to grow 36%, compared to a 21% growth forecast for the Healthcare Services industry in Germany.Is New 90 Day High Low • Feb 16New 90-day high: €3.76The company is up 66% from its price of €2.27 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 7.0% over the same period.お知らせ • Jan 09+ 3 more updatesCarasent ASA, Annual General Meeting, Jun 03, 2021Carasent ASA, Annual General Meeting, Jun 03, 2021.Is New 90 Day High Low • Dec 23New 90-day high: €3.42The company is up 46% from its price of €2.34 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 6.0% over the same period.お知らせ • Dec 12Carasent ASA Appoints Dennis Höjer as CEOThe Board of Directors of Carasent ASA announced that it has appointed Dennis Höjer as new CEO. Dennis is currently CEO of Evimeria EMR AB and COO of Carasent ASA and will assume his new position January 1, 2021. Dennis Höjer, 33, is currently CEO of Evimeria EMR AB and COO of Carasent ASA, a position which he has held since 2018. Prior to 2018 Dennis had several different roles in Evimeria related to sales and marketing and he has been within the group since 2013.お知らせ • Dec 11+ 1 more updateCarasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million.Carasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million on December 10, 2020. Under the terms, Carasent ASA paid NOK 122.5 million as 50% of the Purchase Price in cash and 50% of the Purchase Price in shares. The purchase price represent enterprise value for Avans Soma of NOK 125 million less Avans Soma’s consolidated net debt position of NOK 2.5 million. As on September 30, 2020 Avans Soma's reported revenue and EBITDA was approximately NOK 24 million and NOK 6 million. DNB Markets acted as financial advisor of Carasent ASA. Carasent ASA (OB:CARA) completed the acquisition of Avans Soma AS from Rieber & Søn ASA and others on December 10, 2020.Is New 90 Day High Low • Dec 02New 90-day high: €2.59The company is up 12% from its price of €2.31 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.Reported Earnings • Oct 25Third quarter earnings releasedOver the last 12 months the company has reported total losses of kr14.4m, with earnings decreasing by kr16.0m from the prior year. Total revenue was kr64.4m over the last 12 months, up 48% from the prior year.Reported Earnings • Oct 22Third quarter earnings releasedOver the last 12 months the company has reported total losses of kr14.0m, with earnings decreasing by kr15.1m from the prior year. Total revenue was kr64.4m over the last 12 months, up 48% from the prior year.業績と収益の成長予測DB:E0C - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20285779095167212/31/20275126076142212/31/2026421245210526/30/2026364435191N/A3/31/2026349413779N/A12/31/202534435040N/A9/30/2025329-19-336N/A6/30/2025311-35-928N/A3/31/2025294-35-1029N/A12/31/2024275-42-538N/A9/30/2024270-10-2824N/A6/30/2024255-11-3320N/A3/31/2024252-56-61-4N/A12/31/2023245-47-74-4N/A9/30/2023240-65-88-4N/A6/30/2023228-49-8310N/A3/31/20232095-7027N/A12/31/202220833-6236N/A9/30/202218248-4037N/A6/30/202217516-3037N/A3/31/202216435-450N/A12/31/20211410-633N/A9/30/2021118-33-129N/A6/30/202198-201132N/A3/31/202185-47221N/A12/31/202068-37318N/A9/30/202062-14520N/A6/30/202056-4318N/A3/31/2020502N/A14N/A12/31/2019513N/A13N/A9/30/2019472N/A11N/A6/30/2019440N/A8N/A3/31/201938-3N/A2N/A12/31/201825-7N/A0N/A9/30/20181513N/A34N/A6/30/2018620N/A57N/A3/31/2018N/A20N/A55N/A12/31/2017N/A20N/A51N/A9/30/201726131N/A-6N/A6/30/201780133N/A-16N/A3/31/2017142145N/A-25N/A12/31/2016204150N/A-37N/A9/30/20162203N/A-35N/A6/30/201623656N/A-61N/A3/31/201625455N/A-41N/A12/31/201529158N/A-30N/A9/30/2015317-30N/A4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: E0Cの予測収益成長率 (年間40.9% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: E0Cの収益 ( 40.9% ) はGerman市場 ( 16.2% ) よりも速いペースで成長すると予測されています。高成長収益: E0Cの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: E0Cの収益 ( 16.3% ) German市場 ( 6.6% ) よりも速いペースで成長すると予測されています。高い収益成長: E0Cの収益 ( 16.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: E0Cの 自己資本利益率 は、3年後には低くなると予測されています ( 8.1 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/19 19:05終値2026/07/17 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Carasent AB (publ) 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Ole-Andreas KrohnDNB CarnegieChristoffer BjørnsenDNB CarnegieEmilie EngenDNB Carnegie3 その他のアナリストを表示
Reported Earnings • Jul 14Second quarter 2026 earnings released: kr0.04 loss per share (vs kr0.08 loss in 2Q 2025)Second quarter 2026 results: kr0.04 loss per share (improved from kr0.08 loss in 2Q 2025). Revenue: kr97.7m (up 18% from 2Q 2025). Net loss: kr2.76m (loss narrowed 50% from 2Q 2025). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Board Change • May 20High number of new directorsIndependent Director Cecilia Lager was the last director to join the board, commencing their role in 2025.
お知らせ • Apr 28Carasent AB (publ) (OM:CARA) agreed to acquire Infosolutions Sverige Ab for an enterprise value of approximately SEK 120 million.Carasent AB (publ) (OM:CARA) agreed to acquire Infosolutions Sverige Ab for an enterprise value of approximately SEK 120 million on April 27, 2026. A cash consideration will be paid by Carasent AB (publ). The purchase price will be paid 90 percent in cash and 10 percent in already repurchased Carasent shares, valued at SEK 23.74 per share based on a 90-day volume-weighted average price (VWAP), corresponding to 538,555 shares. For the period ending December 31, 2025, Infosolutions Sverige Ab reported total revenue of SEK 67 million. The expected completion of the transaction is April 27, 2026 to June 30, 2026.
お知らせ • Feb 12+ 3 more updatesCarasent AB (publ) to Report Q4, 2026 Results on Feb 04, 2027Carasent AB (publ) announced that they will report Q4, 2026 results on Feb 04, 2027
お知らせ • Feb 09Carasent AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Carasent AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 12, 2026
お知らせ • Dec 17Carasent AB (publ) (OM:CARA) announces an Equity Buyback for 10% of its issued share capital.Carasent ASA (OB:CARA) commences share repurchases on December 16, 2025, under the program mandated by shareholders in the Annual General Meeting held on April 23, 2025. As per the mandate, the company is authorized to repurchase up to 10% of its issued share capital, such that the company’s holding in treasury together with the shares repurchased does not exceed 10% of its issued share capital at any point of time. The purpose of the program is transfer of shares may be made with deviation from shareholders' preferential rights is to enable financing of acquisitions. On July 9, 2025, the company initiated a Market repurchases. Under the program, the company will repurchase up to SEK 150 million worth of its shares. The payment for acquired shares shall be made in cash. The repurchases may last until the 2026 Annual General Meeting at the latest.
お知らせ • Oct 23Carasent AB (publ), Annual General Meeting, Apr 20, 2026Carasent AB (publ), Annual General Meeting, Apr 20, 2026. Location: stockholm Sweden
お知らせ • Oct 10Carasent AB (publ) to Report Q3, 2025 Results on Oct 16, 2025Carasent AB (publ) announced that they will report Q3, 2025 results at 7:00 AM, Central European Standard Time on Oct 16, 2025
お知らせ • Jul 08Carasent AB (publ) to Report Q2, 2025 Results on Jul 10, 2025Carasent AB (publ) announced that they will report Q2, 2025 results at 7:00 AM, Central European Standard Time on Jul 10, 2025
お知らせ • Apr 24Carasent AB (Publ) Announces Board AppointmentsCarasent AB (publ) at its Annual General Meeting on 23 April 2025, approved to elect Johan Kallblad, Dr. Carol Wildhagen and Cecilia Lager as new Board members, and to elect Tomas Meerits as the Chairman of the Board.
お知らせ • Apr 08Carasent AB (publ) to Report Q1, 2025 Results on Apr 11, 2025Carasent AB (publ) announced that they will report Q1, 2025 results at 7:00 AM, Central European Standard Time on Apr 11, 2025
お知らせ • Feb 24Carasent AB (publ), Annual General Meeting, Apr 23, 2025Carasent AB (publ), Annual General Meeting, Apr 23, 2025.
お知らせ • Oct 29Carasent ASA (OB:CARA) acquired Data - Al GmbH.Carasent ASA (OB:CARA) acquired Data - Al GmbH on October 28, 2024. The transaction values DataAl at an enterprise value of €8 million, with potential additional earnout payments of up to €4 million pending future growth. Data - Al has reported revenues of approximately €4 million and EBITDA of approximately €0.5 million in 2023. Carasent ASA (OB:CARA) completed the acquisition of Data - Al GmbH on October 28, 2024.
Reported Earnings • Oct 25Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023)Third quarter 2024 results: kr0.03 loss per share (improved from kr0.06 loss in 3Q 2023). Revenue: kr66.3m (up 19% from 3Q 2023). Net loss: kr2.03m (loss narrowed 55% from 3Q 2023). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.
New Risk • Sep 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).
Board Change • Jul 30High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Ulrika Sundling is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 01Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion on April 4, 2024. Offer price per share is NOK 20. The transaction is subject to subject to customary conditions, including acceptance level and any regulatory approvals required. The Offer has already received strong support from key shareholders representing 34% of the share capital of Carasent. Launch of the Offer is subject to, inter alia, a customary confirmatory due diligence of key commercial, financial, technical and legal aspects of Carasent with a focus on confirming key assumptions. The board of directors advises all shareholders to monitor the situation but not take any action in respect of the offer which may be made by EG until shareholders can assess the merits of such offer on the basis of further developments. DNB Markets acted as financial advisor and Advokatfirmaet BAHR AS acted as legal advisor to Carasent. Carnegie AS acted as financial advisor and Arntzen de Besche acted as legal advisor to Eg Norge.
Reported Earnings • Apr 26First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)First quarter 2024 results: kr0.15 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr66.9m (up 12% from 1Q 2023). Net loss: kr10.6m (loss widened kr9.52m from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 20Carasent ASA Announces Changes to Its BoardCarasent ASA, at its Annual General Meeting held on April 17, 2024, approved the following. In accordance with the proposal from the Company's Nomination Committee, Henric Carlsson elected as a new Director for a period of two years, cf. the Public Limited Liability Companies Act § 6-6. The new Board of Directors consists of: Petri Niemi, Chairman; Camilla Skoog; Ulrika Cederskog Sundling; Tomas Meerits; Henric Carlsson. In accordance with the proposal from the Company's Board of Directors and Nomination Committee, Jesper Jannerberg and Peder Strand elected as new members of the Committee for a period of two years.
Reported Earnings • Mar 25Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)Full year 2023 results: kr0.60 loss per share (down from kr0.39 profit in FY 2022). Revenue: kr244.0m (up 25% from FY 2022). Net loss: kr46.4m (down 249% from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Feb 26Chief Executive Officer recently bought €121k worth of stockOn the 23rd of February, Daniel Ohman bought around 135k shares on-market at roughly €0.89 per share. This transaction increased Daniel's direct individual holding by 5x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth €2.4m. Daniel has been a buyer over the last 12 months, purchasing a net total of €137k worth in shares.
Reported Earnings • Feb 16Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)Full year 2023 results: kr0.64 loss per share (down from kr0.39 profit in FY 2022). Revenue: kr244.0m (up 25% from FY 2022). Net loss: kr46.4m (down 249% from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Feb 01Founder recently bought €2.4m worth of stockOn the 30th of January, Niclas Hugosson bought around 3m shares on-market at roughly €0.95 per share. This transaction increased Niclas' direct individual holding by 552x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Niclas has been a buyer over the last 12 months, purchasing a net total of €2.0m worth in shares.
Board Change • Jan 07High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Ulrika Sundling is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
New Risk • Dec 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings are forecast to decline by an average of 1.5% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (€68.9m market cap, or US$75.0m).
お知らせ • Nov 30Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of DirectorsCarasent ASA announced that Board member Staffan Hanstorp has given notice of his resignation as a member of the board of directors of Carasent ASA with immediate effect.
お知らせ • Nov 25+ 5 more updatesCarasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024Carasent ASA announced that they will report fiscal year 2023 results on Mar 22, 2024
お知らせ • Nov 16Carasent Asa Approves DividendCarasent ASA approved dividend of NOK 1.84 per share, totaling NOK 133,077,597 million. The payment is to be based on the approved 2022 Annual Accounts.
Reported Earnings • Jul 16Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)Second quarter 2023 results: kr0.64 loss per share (down from kr0.03 profit in 2Q 2022). Revenue: kr63.2m (up 36% from 2Q 2022). Net loss: kr51.3m (down kr53.7m from profit in 2Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare Services industry in Europe.
Reported Earnings • May 05First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)First quarter 2023 results: kr0.01 loss per share (down from kr0.32 profit in 1Q 2022). Revenue: kr59.9m (up 34% from 1Q 2022). Net loss: kr1.04m (down 104% from profit in 1Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare Services industry in Europe.
Reported Earnings • Apr 06Full year 2022 earnings releasedFull year 2022 results: Revenue: kr195.3m (up 42% from FY 2021). Net income: kr31.2m (up kr31.3m from FY 2021). Profit margin: 16% (up from net loss in FY 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare Services industry in Europe.
Reported Earnings • Feb 16Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)Full year 2022 results: EPS: kr0.39 (up from kr0.002 loss in FY 2021). Revenue: kr195.3m (up 42% from FY 2021). Net income: kr31.2m (up kr31.3m from FY 2021). Profit margin: 16% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe.
お知らせ • Jan 05+ 5 more updatesCarasent ASA to Report Q1, 2023 Results on May 04, 2023Carasent ASA announced that they will report Q1, 2023 results on May 04, 2023
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. 1 highly experienced director. Independent Chairman of the Board Johan Lindqvist is the most experienced director on the board, commencing their role in 2007. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.64, the stock trades at a forward P/E ratio of 91x. Average forward P/E is 27x in the Healthcare Services industry in Europe. Total loss to shareholders of 60% over the past year.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.13 (up from kr0.28 loss in 3Q 2021). Revenue: kr47.4m (up 28% from 3Q 2021). Net income: kr10.4m (up kr31.8m from 3Q 2021). Profit margin: 22% (up from net loss in 3Q 2021). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare Services industry in Europe.
Reported Earnings • Jul 16Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)Second quarter 2022 results: EPS: kr0.03 (down from kr0.34 in 2Q 2021). Net income: kr2.40m (down 88% from 2Q 2021).
Valuation Update With 7 Day Price Move • May 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to €2.07, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 29x in the Healthcare Services industry in Europe. Total loss to shareholders of 40% over the past year.
Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)First quarter 2022 results: EPS: kr0.32 (up from kr0.14 loss in 1Q 2021). Revenue: kr44.8m (up 59% from 1Q 2021). Net income: kr25.4m (up kr33.1m from 1Q 2021). Profit margin: 57% (up from net loss in 1Q 2021). The move to profitability was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 41%, compared to a 26% growth forecast for the industry in Germany.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Staffan Hanstorp was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 04Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)Full year 2021 results: kr0.002 loss per share (up from kr0.85 loss in FY 2020). Revenue: kr137.1m (up 94% from FY 2020). Net loss: kr148.0k (loss narrowed 100% from FY 2020). Over the next year, revenue is forecast to grow 53%, compared to a 31% growth forecast for the industry in Germany.
Reported Earnings • Feb 11Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: kr0.01 (up from kr0.85 loss in FY 2020). Revenue: kr137.1m (up 94% from FY 2020). Net income: kr642.0k (up kr38.8m from FY 2020). Profit margin: 0.5% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 46%, compared to a 44% growth forecast for the industry in Germany.
Reported Earnings • Oct 28Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)The company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr36.9m (up 109% from 3Q 2020). Net loss: kr21.4m (loss widened 136% from 3Q 2020).
Reported Earnings • Aug 21Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr32.0m (up 88% from 2Q 2020). Net income: kr19.9m (up kr25.5m from 2Q 2020). Profit margin: 62% (up from net loss in 2Q 2020).
Executive Departure • Aug 04Chief Financial Officer Lars Forsberg has left the companyOn the 1st of August, Lars Forsberg's tenure as Chief Financial Officer ended. We don't have any record of a personal shareholding under Lars' name. A total of 2 executives have left over the last 12 months.
Reported Earnings • May 01First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: kr28.2m (up 81% from 1Q 2020). Net loss: kr7.67m (down kr8.06m from profit in 1Q 2020).
Reported Earnings • Mar 29Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: kr70.6m (up 47% from FY 2019). Net loss: kr38.1m (down kr41.3m from profit in FY 2019).
お知らせ • Mar 04Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA) on March 2, 2021. As a part of the transaction Aeternum Capital acquired 8.25 million shares. Aeternum Capital AS, a fund managed by Aeternum Management AS completed the acquisition of 15% stake in Carasent ASA (OB:CARA) on March 2, 2021.
Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 0.6%. Over the next year, revenue is forecast to grow 36%, compared to a 21% growth forecast for the Healthcare Services industry in Germany.
Is New 90 Day High Low • Feb 16New 90-day high: €3.76The company is up 66% from its price of €2.27 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 7.0% over the same period.
お知らせ • Jan 09+ 3 more updatesCarasent ASA, Annual General Meeting, Jun 03, 2021Carasent ASA, Annual General Meeting, Jun 03, 2021.
Is New 90 Day High Low • Dec 23New 90-day high: €3.42The company is up 46% from its price of €2.34 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 6.0% over the same period.
お知らせ • Dec 12Carasent ASA Appoints Dennis Höjer as CEOThe Board of Directors of Carasent ASA announced that it has appointed Dennis Höjer as new CEO. Dennis is currently CEO of Evimeria EMR AB and COO of Carasent ASA and will assume his new position January 1, 2021. Dennis Höjer, 33, is currently CEO of Evimeria EMR AB and COO of Carasent ASA, a position which he has held since 2018. Prior to 2018 Dennis had several different roles in Evimeria related to sales and marketing and he has been within the group since 2013.
お知らせ • Dec 11+ 1 more updateCarasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million.Carasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million on December 10, 2020. Under the terms, Carasent ASA paid NOK 122.5 million as 50% of the Purchase Price in cash and 50% of the Purchase Price in shares. The purchase price represent enterprise value for Avans Soma of NOK 125 million less Avans Soma’s consolidated net debt position of NOK 2.5 million. As on September 30, 2020 Avans Soma's reported revenue and EBITDA was approximately NOK 24 million and NOK 6 million. DNB Markets acted as financial advisor of Carasent ASA. Carasent ASA (OB:CARA) completed the acquisition of Avans Soma AS from Rieber & Søn ASA and others on December 10, 2020.
Is New 90 Day High Low • Dec 02New 90-day high: €2.59The company is up 12% from its price of €2.31 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.
Reported Earnings • Oct 25Third quarter earnings releasedOver the last 12 months the company has reported total losses of kr14.4m, with earnings decreasing by kr16.0m from the prior year. Total revenue was kr64.4m over the last 12 months, up 48% from the prior year.
Reported Earnings • Oct 22Third quarter earnings releasedOver the last 12 months the company has reported total losses of kr14.0m, with earnings decreasing by kr15.1m from the prior year. Total revenue was kr64.4m over the last 12 months, up 48% from the prior year.